The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Ferumoxtran-10

Ferumoxtran-10

Ferumoxtran-10 is a superparamagnetic iron oxide nanoparticle used as a contrast agent for magnetic resonance imaging (MRI).
It has been studied for its potential applications in disease diagnosis and treatment monitoring.
PubCompare.ai's AI-powered platform can help researchers locate the best research protocols and optimize methods for working with Ferumoxtran-10, ensuring reproducible and effective results.
Leveraging intelligent comparisons, PubCompare.ai guides users to the most reliable and up-to-date information, empowering researchers to explore Ferumoxtran-10 with confidence.
Turst PubCompare.ai as your partner in enhancing your research outcomes.

Most cited protocols related to «Ferumoxtran-10»

22 rats were used for fMRI experiments, obtained in a total of 51 fMRI experimental runs. BOLD data were acquired from all 22 rats, and 5 of these rats were also used for CBV measurements after at least one successful BOLD run. Experiments with no seizures, continuous seizures resulting in lack of baseline EEG, poor systemic physiology, motion in fMRI images, or abortion of fMRI data acquisition due to technical reasons were excluded from analysis. BOLD fMRI experiments were performed without exogenous contrast administration. For CBV-weighted fMRI experiments a dose of 10–18 mg/kg iron oxide contrast agent (Combidex [ferumoxtran-10], Advanced Magnetics Inc., Cambridge, MA) was administered intravenously 10–15 minutes prior to image acquisition.
During MRI recordings, the rat was positioned prone in a specially designed plastic holder with the head fixed and bregma positioned at the center of the surface coil. The animals were then inserted into the magnet with its head positioned at the isocenter of the magnet. EEG signals were acquired simultaneously with fMRI using a pair of 1 mm diameter carbon-filament electrodes (WPI, Sarasota, FL). These carbon filaments were placed between the scalp and the upper surface of the skull in the frontal and occipital areas, with the exposed portion of each electrode running in the coronal plane crossing the midline (from left to right), and secured to the skin with tissue glue (3M Vetbond, 3M Animal Care Products, MN ) to minimize MRI signal distortion (Englot et al., 2008 (link)). The EEG signals were acquired in differential mode between the two carbon-filament electrodes, amplified (×100) and filtered (1–30 Hz) using a Model 79D Data Recording System (Grass Instruments Co., Quincy, MA). EEG signals were digitized and recorded (sampling rate 1000 Hz) using a CED Micro 1401 and Spike 2 software (Cambridge Electronic Design, Cambridge, UK).
All fMRI experiments were acquired on a 9.4 Tesla Bruker (Bruker Avance, Billerica, MA) horizontal bore (16-cm-internal diameter) spectrometer, equipped with passively shielded shim/gradient coils (47.5 G/cm) operating at 400.5 MHz for protons. The transceiver system consisted of a surface coil (15.18 mm diameter) for transmission of radio frequency pulses and receiving. To optimize the homogeneity of the static magnetic field, the system was shimmed before each experiment using global manual shimming.
Anatomical images for each animal were acquired with 5 or 11 interlaced slices in the coronal plane using the fast low angle shot (FLASH) sequence with repetition time (TR) 500 ms; echo time (TE) 6 ms; flip angle = 40–55°; field of view (FOV) 25 × 25 mm; 256 × 256 matrix size; in-plane resolution of 98 × 98 µm; and slice thickness 1000 µm, no gap. BOLD and CBV-weighted fMRI data were obtained in the same planes as anatomical images. We used single-shot spin echo, echo planar imaging (SE-EPI; 22 experimental runs in 16 animals) or gradient echo (GE-EPI; 25 experimental runs in 13 animals; 7 animals had both SE and GE acquisitions), and obtained similar results with both approaches. SE-EPI data were acquired with the following parameters: TR = 1000 ms, TE = 25 ms; excitation flip angle 90°; inversion flip angle 180°; FOV = 25 × 25 mm, 64 × 64 matrix size; in-plane resolution of 390 × 390 µm; and slice thickness 1000 µm. All SE-EPI experiments were acquired with 11 slices. The 11 slices were acquired over 1000 ms, followed by a 2s or 5s pause before the next image onset so that EEG could readily be interpreted during data acquisition; time between onset of consecutive image acquisitions was therefore 3s or 6s. We acquired 300 to 600 images per run, resulting in a total imaging time of 1800s for most experimental runs (a shorter imaging time of 900 or 1500 s was used for two runs). GE-EPI data were acquired with following parameters: TR = 1000 ms, TE = 13 ms, FOV = 25 × 25 mm, 64 × 64 matrix size; in-plane resolution of 390 × 390 µm. For most GE-EPI runs slice thickness was 2000 µm, and 5 slices were acquired over 1000 ms, followed by a 2s pause; time between consecutive image onsets was therefore 3s. We acquired 300 to 400 images per run, with a total imaging time of 900s for most runs. For two GE-EPI runs, slice thickness was 1000 µm (like in SE-EPI runs) resulting in 11 slices acquired every 3s, with 400 total images obtained over 1200 s. Images from the first 48s of each run were discarded from analysis.
Publication 2011
At least 6 d prior to fMRI recordings, animals were stereotactically implanted with a MRI-compatible bipolar tungsten stimulating/recording electrode (∼0.1 MΩ resistance, Microprobe Inc., Gaithersburg, MD) in the dorsal hippocampus (same coordinates as above). To minimize hardware and susceptibility artifact in the vicinity of the fMRI measurements, the electrode was lowered at a 50° angle from the vertical using a posterior approach and fixed to the skull adjacent to lambda with 2-4 plastic screws and dental acrylic. Immediately prior to fMRI scans, animals were anesthetized with ketamine/xylazine (90/15 mg/kg, i.m., q1 hr), tracheotomized, and artificially ventilated (70% air and 30% O2). To prevent any movements during the experiments and to facilitate artificial breathing, animals were paralyzed by repeated injections of D-tubocurarine chloride (0.5 mg/kg, i.v.) (Sigma-Aldrich, Inc., St. Louis, MO). A femoral artery was cannulated (Intramedic PE50 tubing, Becton Dickinson and Company, Sparks, MD) for continuous arterial blood pressure monitoring and periodic blood sampling for measurements of blood gases and pH using an ABL 5 blood gas analyzer (Radiometer Copenhagen, Copenhagen, Denmark). All physiological values (blood gases, mean arterial blood pressure [MABP], and pH) were maintained within physiological range throughout the experiments (Schridde et al., 2007 ). One femoral vein was cannulated and an IP line was placed (Intramedic PE10 tubing) for the injections of anesthetics and paralyzing agents. For flow-related cerebral blood volume (CBV) fMRI experiments, rats were also injected with iron oxide contrast agent (24-50 mg/kg) (Combidex [ferumoxtran-10], Advanced Magnetics Inc., Cambridge, MA). Body temperature was kept constant at ∼37 °C using a heating pad.
Publication 2008
Anesthetics Animals BLOOD Blood Gas Analysis Body Temperature Cerebral Blood Volume Combidex Contrast Media Cranium Dental Health Services Femoral Artery ferric oxide ferumoxtran-10 fMRI Ketamine Movement Physiological Processes physiology Radionuclide Imaging Rattus Seahorses Susceptibility, Disease Tubocurarine Chloride Tungsten Vein, Femoral Xylazine
All 68Ga-PSMA PET/CT exams were retrospectively reviewed by 2 (link) certified nuclear physicians in consensus, and the nano-MR images were independently reviewed by 1 experienced radiologist. For both modalities, the number, anatomic location, and size of detected LNs were reported. The location was described according to preconfigured anatomic locations in the pelvis, consistent with clinical practice in our department. LN size was measured (mm) for the smallest axis. Additionally, all detectable LNs were classified with a level of suspicion (LoS) for both nano-MRI and 68Ga-PSMA PET/CT. This classification is a 5-point likeliness scale for potential malignancy that is used by nuclear physicians and radiologists in our center. For nano-MRI, LoS was based on the signal intensity in the iron-sensitive T2*-weighted MRI sequence and its distribution within the LN based on the diagnostic description proposed by Anzai et al. (16 (link)). LoS for 68Ga-PSMA PET/CT was based on the proposed criteria of the 68Ga-PSMA reporting and data system by Rowe et al. (17 (link)). This evaluation comprised a combination of tracer uptake, location, and size. In more detail, LNs with no tracer uptake were given an LoS of 1, defined as a high probability of being benign. LNs with equivocal tracer uptake at sites atypical of PCa involvement (e.g., axillary or hilar) were given a LoS of 2 (probably benign). A LoS of 3 (equivocal), was given to LNs with equivocal tracer uptake at sites typical of PCa involvement, LNs with intense uptake at sites highly atypical of PCa (i.e., the likelihood of nonprostatic malignancies or other [benign] origins is high), or LNs without tracer uptake but with pathologic aspects suspicious of malignancy on anatomic imaging. LNs with clearly increased tracer uptake at sites typical of PCa involvement but lacking definitive findings on anatomic imaging were given an LoS of 4, or probably malignant. A LoS of 5, defined as a high probability of being malignant, was given to LNs with intense tracer uptake at sites typical of PCa and with corresponding pathologic findings on anatomic imaging. For both modalities, LNs with a LoS of 3 or higher were considered suspicious and taken for statistical evaluation.
Full text: Click here
Publication 2021
Axilla Diagnosis Epistropheus gallium GA-68 gozetotide Iron Malignant Neoplasms Pelvis Physicians Radiologist Scan, CT PET
The MRL protocol was as follows. USPIO contrast was administered intravenously, 36 to 24 h before the MRI was performed. Because of this time interval, only post-contrast images were acquired. The same time interval was applied for both types of MRL. For ferumoxtran-10 MRL, this has been established as the optimal interval. For ferumoxytol MRL, this was considered optimal by our expert readers based on visual inspection of a set of nine MRLs acquired from three patients at different time intervals post injection. One patient was imaged at day 0 (directly post injection), at day 1, and at day 2, and the other two were imaged at day 0, day 1, and day 3.
Immediately before imaging, Buscopan (20 mg i.v. and 20 mg i.m.) and Glucagon (20 mg i.m.) were administered to suppress bowel peristalsis. The dose of ferumoxtran-10 was 2.6 mg Fe per kg body weight, conform earlier research (Harisinghani et al., 2003 (link)). The dose of ferumoxytol was 6.0 mg Fe per kg body weight. This is the maximum allowed dose, which was chosen to maximize the signal suppression in the MEDIC images.
Imaging was performed using a 3.0 T MR-scanner (Magnetom TrioTim; Siemens, Erlangen, Germany). Scan parameters are listed in Table 1.
Full text: Click here
Publication 2016
Body Weight Buscopan ferumoxtran-10 Ferumoxytol Glucagon Intestines Patients Peristalsis Radionuclide Imaging
All patients received ferumoxtran-10 intravenously in a weight-adapted dose of 2.6 mg/kg of body weight 24–36 h before the MRI scan. Ferumoxtran-10 was diluted in 100 mL of 0.9% NaCl solution and administered via drip infusion using a 0.22-μm-pore filter (Minisart NML syringe filter, catalog no. 16534-k; Sartorius AG). The infusion was performed at a slow rate of 1 mL/min at the start, increasing to 4 mL/min. The infusion duration was approximately 45 min and supervised by radiologists. MRI was performed using a 3-T MRI scanner (Magnetom Skyra or Trio; Siemens Healthineers). The imaging area included the pelvis from the pubic bone to the aortic bifurcation. The MRI protocol consisted of an isotropic 3-dimensional T1-weighted gradient-echo sequence (repetition time, 6.5 ms; echo time, 2.5 ms; flip angle, 10°; and spatial resolution, 0.9-mm isotropic) and an isotropic 3-dimensional iron-sensitive T2*-weighted gradient-echo sequence with fat saturation (multiple-echo data image combination, with repetition time, 21 ms; echo time, 12 ms; 3 combined echoes; flip angle, 10°; and spatial resolution, 0.85-mm isotropic).
Full text: Click here
Publication 2021
Aorta ECHO protocol ferumoxtran-10 Iron MRI Scans Normal Saline Patients Pelvis Pubic Bone Radiologist Saturated Fatty Acid Syringes TRIO protein, human

Most recents protocols related to «Ferumoxtran-10»

Preoperative USPIO-enhanced MRI was conducted using ferumoxtran-10 (Ferrotran, SPL Medical B.V., investigational product), administered intravenously (2.6 mg/kg body weight) 24-36 h before the scan, as previously described [16] . MRI was performed on a 3-T MRI system (Magnetom Prisma, Siemens Healthcare). Butylscopolamine and glucagon were administered to minimise peristaltic motion, unless contraindicated. Patients were positioned feet first supine, with body phased array coils around the upper abdomen. The scan range was from diaphragm to aortic bifurcation. Images were acquired with repeated breath-holds of maximally 20 s on expiration. MRI sequences included T2-weighted HASTE for anatomical reference, T1-weighted VIBE DIXON for LN localisation, and fat-suppressed T2*-weighted multi gradient echo (mGRE) sequence for USPIO visualisation, mGRE images were reconstructed to a single T2*weighted computed echo time (TE) of 12 ms [17] . Table 1 describes the technical details of the MR sequences.
Publication 2024
Not available on PMC !
The MNPs are measured at a concentration of 8.5 mg Fe mL -1 ≈ 152 mmol/L, a threshold that is chosen to avoid concentration dependent behavior (Löwa et al. 2016) . For Perimag, we use stock dispersion with this concentration (LOT 045211). Both Resotran (LOT F1901) and Resovist (LOT 20F01) are supplied with 28 mg Fe mL -1 and are therefore diluted with distilled water. Ferrotran (LOT PRX19L02) is shipped as freeze-dried powder and has a concentration of 20 mg Fe mL -1 once dispersed in water, which we dilute to the same level of 8.5 mg Fe mL -1 . All MNPs are made from iron oxide and coated with a dextran shell. More specifically, Resovist and Resotran are made from Ferucarbotran and Ferrotran is made from Ferumoxtran-10 Lyophilisate and additionally coated with sodium citrate.
Publication 2024
In eight of the 10 animals that completed HCD feeding, SPIONdex (2.6 mg iron/kg bw) was administered intravenously as a slow bolus (2 mL/min). As a reference SPION-based contrast agent, ferumoxytol (Feraheme®; 2.6 mg iron/kg bw) was administered intravenously to two randomly assigned animals (animals 9 and 10 in Table 1). The dose was chosen based on previous clinical studies of ferumoxtran. The total dose of iron injected in these studies corresponded to 195 mg iron for a 75-kg patient, which is less than the amount of iron in 1 U of transfused blood (200 mg). For comparison, the total body iron in humans is 3500 mg and the maximum total dose of intravenous iron dextran supplements is 20 mg iron/kg body weight,20 (link) which corresponds to 1500 mg iron for a 75-kg patient, and is thus 7.69-fold larger than the dose used for imaging.
MR of the rabbits was performed (a) directly before nanoparticle administration and (b) 24 h later using a 1.5 T scanner (Aera, Siemens Healthcare, Erlangen, Germany) with a 15-channel knee coil. The rabbits were anesthetized as described above (see 2.4), placed in the supine position (feet first), and immobilized using foam material. The protocol consisted of a 2D multi-slice T1 fast low angle shot (FLASH) gradient echo sequence with fat suppression in transversal and coronal direction (0.625×0.625× 2.0 mm³, TE = 7.15 ms, TR = 342 ms, TA 7:06 min, FoV 130×160) and a susceptibility-weighted sequence (SWI) in transversal direction (0.58× 0.58×2.0 mm³, TE = 40 ms, TR = 49 ms, TA 5:18 min, FoV 150×150). All images were transferred to a dedicated postprocessing workstation for further image evaluation.
Publication 2024
Aided by the ex vivo MRI, LNs from in vivo MRI were matched to pathology for node-to-node analysis. Clinical follow-up imaging was used to confirm if an LN was indeed resected or not. Matching criteria were size, shape, and location, including anatomical landmarks such as surrounding vessels and organs. Only matched LNs were included in the validation analysis. A pancreas pathologist (L.B., ten years of expertise) re-evaluated all matched LNs. Statistical analysis was performed using SPSS (version 25). The sensitivity and specificity of USPIO-MRI were calculated with crosstabs, using pathology as the reference standard. Continuous variables were summarised using standard descriptive statistics (mean, standard deviation, median, and range), and categorical variables were summarised with frequencies.
Publication 2024
A radiologist (A.N., 18 years experience in abdominal imaging) analysed all USPIO-enhanced MRI images. A second radiologist (J.H., 23 years experience in pancreatic imaging) supervised the analysis. Disagreements were resolved in a consensus meeting. Both radiologists were blinded to the histopathology results. All visible LNs, regional and distant, were annotated and measured (short axis on axial orientation). LN locations were indicated using the classification of the Japan Pancreas Society [18] . LNs were scored on the iron-sensitive T2*-weighted mGRE (TE = 12 ms) sequence, using diagnostic guidelines adapted from Anzai et al (Table 2, [19] ). Type 1-4 LNs were classified as suspicious for metastases and type 5-7 LNs as non-suspicious. The distinction between regional and distant LNs was based on the TNM classification (eighth edition) by the UICC [5] . The definition of regional nodes differs depending on the cancer type (pancreatic head or tail, cholangial, ampullary, or duodenal), the respective definition for each tumour type was applied.
Publication 2024

Top products related to «Ferumoxtran-10»

Sourced in Germany, United States, United Kingdom
The Magnetom Tim Trio is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for medical applications. The Magnetom Tim Trio utilizes advanced technology to capture detailed images of the human body.
Sourced in Germany, United States
The Prisma is a versatile laboratory equipment designed for a wide range of scientific applications. It serves as a reliable tool for various analytical and research processes. The core function of the Prisma is to provide accurate and consistent results through its advanced technology and precise measurements.
Sourced in France
Minisart NML syringe filters are single-use filtration devices designed for rapid sample preparation. They feature a membrane filter with a pore size of 0.2 μm, which can effectively remove particles and microorganisms from liquid samples.
Sourced in United States
The Lymph Node Task Card is a laboratory equipment product designed for the analysis and processing of lymph node samples. It provides a standardized and efficient platform for performing various procedures related to lymph node examination and assessment. The core function of this product is to facilitate the handling, preparation, and analysis of lymph node specimens in a controlled and organized manner, supporting clinical and research applications.
Sourced in Germany, United States, Switzerland
The MAGNETOM Prisma is a magnetic resonance imaging (MRI) system designed and manufactured by Siemens. It is a powerful diagnostic imaging device that uses strong magnetic fields and radio waves to generate detailed images of the human body. The MAGNETOM Prisma is capable of providing high-quality, high-resolution imaging data to support clinical decision-making and patient care.
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
Sourced in Germany, United States
The MAGNETOM Skyra is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for various medical applications. The MAGNETOM Skyra utilizes advanced technology to generate detailed images of the body's internal structures without the use of ionizing radiation.

More about "Ferumoxtran-10"